Business
Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results
- Initiated first Marker-sponsored study, a Phase 2 trial of MT-401 for the treatment of post-transplant acute myeloid leukemia, and enrolled the first
About this update from Marker Therapeutics, Inc.
[{"type":"text","content":"- Initiated first Marker-sponsored study, a Phase 2 trial of MT-401 for the treatment of post-transplant acute myeloid leukemia, and enrolled the first patient in the safety lead-in portion -\n - Received alternate reagent and expect to submit required data to enable removal of partial clinical hold for IND for MT-401 by Q1 2021 -\n - Company to host conference call and webcast today at 5:00 PM EST -\n\n\nHOUSTON, Nov. 9, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2020. \n\n \n \n \n \n \n \n\n \n\"This quarter, our Company reached a significant milestone by initiating our first Marker-sponsored study—a Phase 2 trial of zelenoleucel or MT-401, our lead MultiTAA-specific T cell product candidate for the treatment of post-transplant acute myeloid leukemia,\" said Peter L. Hoang, President & CEO of Marker Therapeutics. \"We have enrolled the first patient in the safety lead-in portion of the trial, and are in the process of scheduling the donor in order to manufacture the product.\" \nContinued Mr. Hoang: \"During this unprecedented time, we have made significant progress by enrolling additional clinical sites for our AML trial, advancing our manufacturing process, reducing production time by 50% and improving the potency of our MT-401 product, and entering the final phase of the construction of our new in-house cGMP manufacturing facility. I am extremely proud of the dedication and resolve that our team has shown during these challenging months. I want to acknowledge their hard work across the organization that went into achieving these milestones.\"\nPROGRAM UPDATES\nMT-401: Multi-Antigen Targeted (MultiTAA)-Specific T Cell Product Candidate for AML\nPhase 2 AML Trial The Company initiated the safety lead-in portion of its Phase 2 study of zelenoleucel (MT-401) in patients with acute myeloid leukemia (AML) following an allogeneic stem cell transplant in both the adjuvant and active disease settings. The Company anticipates treating the first patient by Q1 2021. The safety lead-in is expected to enroll a total of...